Aethlon Medical to Announce Financial Results for Q2
Aethlon Medical, Inc. (Nasdaq: AEMD), a company focused on creating innovative treatments for cancer and serious infectious diseases, has announced a forthcoming release of its financial results for the fiscal second quarter, which concluded on September 30, 2025. The announcement is scheduled for 4:15 p.m. ET on November 12, 2025.
Conference Call Details for Stakeholders
In connection with these results, management will conduct a conference call at 4:30 p.m. ET on the same day. This call is crucial for stakeholders, as it allows management to detail the financial outcomes and any significant corporate developments. A question and answer session will follow the formal remarks, providing an opportunity for further engagement.
How to Register for the Conference Call
Individuals interested in joining this conference call can easily register through a dedicated online link. Past experience has shown that early registration ensures participants receive their unique dial-in information promptly. For those unable to access the internet or pre-register, there are toll-free and international dial-in options available, providing easy access to join the discussion.
Replay Information for the Conference Call
For anyone unable to attend the live call, a replay will be accessible approximately one hour following the conclusion. This replay will be available until December 12, 2025. Stakeholders can listen back to the conversation and gain insights on the financial performance and future prospects of Aethlon Medical.
Exploring Aethlon's Innovative Hemopurifier
At the forefront of Aethlon's technology is the Hemopurifier®—an investigational medical device designed to target and eliminate enveloped viruses and tumor-derived extracellular vesicles (EVs) from the bloodstream. Its unique approach employs a combination of plasma separation, size exclusion, and affinity binding that focuses on specific pathogenic elements. There is growing evidence that EVs released from solid tumors can contribute to metastasis and hinder the effectiveness of immunotherapies. The Hemopurifier's ability to extract these components from circulation is backed by both laboratory and initial clinical studies.
Regulatory Recognition of the Hemopurifier
This advanced device has received the U.S. Food and Drug Administration’s Breakthrough Device Designation, indicating its significant potential in treating advanced cancer and life-threatening viral infections unresponsive to existing therapies. This recognition underscores Aethlon’s commitment to expanding therapeutic avenues for patients facing critical health challenges.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is at the clinical forefront of medical device technology. Based in San Diego, the company is dedicated to pioneering solutions that address pressing unmet health needs in the areas of oncology and infectious diseases. The Hemopurifier exemplifies this innovative spirit, targeting harmful pathogens while aiming to improve patient outcomes.
Stay Informed about Aethlon Medical
For continuous updates and detailed insights into Aethlon Medical’s advancements, stakeholders can visit the company’s official website. Following on social media platforms further enhances opportunities to stay connected with Aethlon’s initiatives and developments.
Frequently Asked Questions
What are the financial results that Aethlon Medical will announce?
Aethlon Medical will disclose its financial performance for the fiscal second quarter ending September 2025, detailing revenue, expenses, and overall financial health.
When is the call to discuss the financial results?
The conference call is scheduled for 4:30 p.m. ET on November 12, 2025.
How can investors participate in the conference call?
Interested parties can register online for the call to receive dial-in information or use the provided telephone numbers for direct access.
What is the replay availability for the conference call?
The replay of the conference call will be available for listening starting one hour after the call ends, remaining accessible until December 12, 2025.
What is the Hemopurifier, and how does it work?
The Hemopurifier is designed to remove enveloped viruses and EVs from the bloodstream, employing a unique method to enhance treatment efficacy for cancer and viral infections.
